Thrivent Financial for Lutherans Purchases New Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Thrivent Financial for Lutherans purchased a new position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 190,205 shares of the biotechnology company's stock, valued at approximately $3,802,000. Thrivent Financial for Lutherans owned approximately 0.08% of ADMA Biologics at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Assenagon Asset Management S.A. grew its holdings in ADMA Biologics by 2.7% in the third quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company's stock valued at $69,454,000 after purchasing an additional 92,281 shares during the last quarter. Seven Eight Capital LP acquired a new stake in ADMA Biologics in the 2nd quarter valued at about $1,992,000. Principal Financial Group Inc. raised its position in ADMA Biologics by 785.7% during the third quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company's stock worth $23,872,000 after acquiring an additional 1,059,394 shares during the last quarter. Louisiana State Employees Retirement System purchased a new stake in shares of ADMA Biologics in the third quarter valued at about $2,253,000. Finally, Point72 Asset Management L.P. acquired a new stake in shares of ADMA Biologics in the second quarter valued at approximately $1,157,000. 75.68% of the stock is owned by hedge funds and other institutional investors.

ADMA Biologics Trading Up 1.4 %

Shares of ADMA Biologics stock traded up $0.29 during trading hours on Monday, reaching $21.47. 3,170,865 shares of the company's stock were exchanged, compared to its average volume of 3,635,050. ADMA Biologics, Inc. has a 52-week low of $3.60 and a 52-week high of $23.64. The company has a fifty day moving average of $18.86 and a 200-day moving average of $14.95. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $5.08 billion, a price-to-earnings ratio of 75.64 and a beta of 0.64.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.13 by $0.02. The firm had revenue of $119.84 million for the quarter, compared to analyst estimates of $107.25 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. During the same period last year, the company earned $0.01 EPS. Sell-side analysts forecast that ADMA Biologics, Inc. will post 0.52 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Brad L. Tade sold 15,000 shares of the stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total value of $317,250.00. Following the transaction, the chief financial officer now directly owns 199,433 shares of the company's stock, valued at approximately $4,218,007.95. This trade represents a 7.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Jerrold B. Grossman sold 136,861 shares of the company's stock in a transaction dated Thursday, August 29th. The stock was sold at an average price of $17.27, for a total value of $2,363,589.47. Following the sale, the director now owns 467,305 shares of the company's stock, valued at $8,070,357.35. This represents a 22.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 185,011 shares of company stock valued at $3,255,204. Insiders own 3.70% of the company's stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Raymond James lifted their price objective on ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a research report on Friday, November 8th. HC Wainwright boosted their price target on ADMA Biologics from $18.00 to $26.00 and gave the stock a "buy" rating in a report on Friday, November 8th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $20.00 price objective on shares of ADMA Biologics in a research note on Friday, September 20th.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.